These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32468165)

  • 1. Adaptation of the prostate biopsy collaborative group risk calculator in patients with PSA less than 10 ng/ml improves its performance.
    Stojadinovic M; Trifunovic T; Jankovic S
    Int Urol Nephrol; 2020 Oct; 52(10):1811-1819. PubMed ID: 32468165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
    Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
    Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.
    Hernandez DJ; Han M; Humphreys EB; Mangold LA; Taneja SS; Childs SJ; Bartsch G; Partin AW
    BJU Int; 2009 Mar; 103(5):609-14. PubMed ID: 19007374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.
    Ankerst DP; Straubinger J; Selig K; Guerrios L; De Hoedt A; Hernandez J; Liss MA; Leach RJ; Freedland SJ; Kattan MW; Nam R; Haese A; Montorsi F; Boorjian SA; Cooperberg MR; Poyet C; Vertosick E; Vickers AJ
    Eur Urol; 2018 Aug; 74(2):197-203. PubMed ID: 29778349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.
    Liang Y; Ketchum NS; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
    Urol Int; 2012; 89(1):9-16. PubMed ID: 22626812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
    Doan P; Graham P; Lahoud J; Remmers S; Roobol MJ; Kim L; Patel MI
    BJU Int; 2021 Dec; 128 Suppl 3():36-44. PubMed ID: 34374190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report.
    Klein EA; Chait A; Hafron JM; Kernen KM; Manickam K; Stephenson AJ; Wagner M; Zhu H; Kestranek A; Zaslavsky B; Stovsky M
    Eur Urol; 2017 Dec; 72(6):942-949. PubMed ID: 28396176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort.
    Jalali A; Foley RW; Maweni RM; Murphy K; Lundon DJ; Lynch T; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Durkan GC; Murphy TB; Watson RW
    BMC Med Inform Decis Mak; 2020 Jul; 20(1):148. PubMed ID: 32620120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could Magnetic Resonance Imaging Help to Identify the Presence of Prostate Cancer Before Initial Biopsy? The Development of Nomogram Predicting the Outcomes of Prostate Biopsy in the Chinese Population.
    Fang D; Zhao C; Ren D; Yu W; Wang R; Wang H; Li X; Yin W; Yu X; Yang K; Liu P; Shan G; Li S; He Q; Wang X; Xin Z; Zhou L
    Ann Surg Oncol; 2016 Dec; 23(13):4284-4292. PubMed ID: 27464612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
    Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
    Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population.
    Wu YS; Fu XJ; Na R; Ye DW; Qi J; Lin XL; Liu F; Gong J; Zhang N; Jiang GL; Jiang HW; Ding Q; Xu J; Sun YH
    Asian J Androl; 2019; 21(6):592-597. PubMed ID: 30924451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
    Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
    BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
    Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved predictive performance of prostate biopsy collaborative group risk calculator when based on automated machine learning.
    Stojadinovic M; Milicevic B; Jankovic S
    Comput Biol Med; 2021 Nov; 138():104903. PubMed ID: 34598066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
    Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
    World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
    Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
    Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are prostate biopsies necessary for all patients 75years and older?
    Chen Y; Fan Y; Yang Y; Jin J; Zhou L; He Z; Zhao Z; He Q; Wang X; Yu W; Wu S
    J Geriatr Oncol; 2018 Mar; 9(2):124-129. PubMed ID: 28939384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy.
    Chen R; Xie L; Xue W; Ye Z; Ma L; Gao X; Ren S; Wang F; Zhao L; Xu C; Sun Y;
    Urol Oncol; 2016 Sep; 34(9):416.e1-7. PubMed ID: 27185342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
    Tosoian JJ; Zhang Y; Xiao L; Xie C; Samora NL; Niknafs YS; Chopra Z; Siddiqui J; Zheng H; Herron G; Vaishampayan N; Robinson HS; Arivoli K; Trock BJ; Ross AE; Morgan TM; Palapattu GS; Salami SS; Kunju LP; Tomlins SA; Sokoll LJ; Chan DW; Srivastava S; Feng Z; Sanda MG; Zheng Y; Wei JT; Chinnaiyan AM;
    JAMA Oncol; 2024 Jun; 10(6):726-736. PubMed ID: 38635241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.